Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
RA’ANANA, Israel and NEW YORK, Nov. 08, 2017 -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that the Company will host a conference call and webcast on Tuesday, November 14, 2017, at 8:30 a.m. Eastern Time to review the Company’s third quarter 2017 financial results and provide a general business update. The Company’s third quarter 2017 financial results will be released prior to the call.
The live webcast may be accessed by visiting the Investors section of the Company's website at http://investors.urogen.com. Please connect at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call (855) 765-5685 (U.S.) or (615) 247-5916 (international) to listen to the live conference call. The conference ID number for the live call is 9197749. An archive of the webcast will be available until November 28, 2017 on the Company’s website.
About UroGen Pharma Ltd.
UroGen Pharma Ltd. (NASDAQ:URGN) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. The Company has developed RTGel™, a proprietary sustained release, hydrogel-based formulation for potentially improving therapeutic profiles of existing drugs. UroGen Pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen Pharma's lead product candidates, MitoGel™ and VesiGel™, are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer. UroGen Pharma is headquartered in Ra’anana, Israel and maintains a corporate office in New York City.
CONTACTS:
UroGen Pharma Ltd.
Gary Titus
Chief Financial Officer
[email protected]
646-768-9531
Or
Burns McClellan, Inc.
Steve Klass
[email protected]
212-213-0006
